Micro-cap pharmaceutical company Aytu BioScience, Inc. AYTU is responsible for global commercialization of products to treat low testosterone, insomnia and male infertility.
What Happened
On Monday, Aytu BioScience revealed its entry into the $3 billion cough and cold market, through its exclusive license of Tuzistra XR. This antitussive is the only FDA-approved treatment of its kind, as it is codeine-based and extended-release, according to the press release.
Tuzistra XR and an additional complimentary product will both be marketed in the U.S., pending FDA-approval.
“Tuzistra XR is expected to generate revenue this year after launching promptly this cough and cold season. Tuzistra XR generated more than 40,000 prescriptions in 2017," the release said.
Why It’s Important
This treatment will aid in the company’s expansion in quite a monumental way.
“This market is dominated by short-acting treatments, which require dosing 4-6 times a day. Tuzistra XR was developed using Tris Pharma's liquid sustained release technology, LiquiXR®, which allows for extended drug delivery throughout a 12-hour dosing period.”
What’s Next
The company will enter into a strategic financing plan with institutional health care investor, Armistice Capital, LLC. Within the arrangement, the investor will provide up to $5 million in order to fund growth and the launch of the Tuzistra products.
Aytu shares were trading higher by 11.4 percent to $1.27 at time of publication.
Related Links:
Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal
Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.